Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Best

Showing results (121-130 of 142) with videos related to

Pageof 15
Sort By:
Journal of Medical Economics|February 29, 2012
Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United StatesAnne-Laure Guillermin, Adam Lloyd, Jennie H Best, et al.
Food Research International (Ottawa, Ont.)|March 1, 2025
Comparative evaluation of amylases in the oral phase of the INFOGEST static simulation of oro-gastric digestionYunyao Qu, Kelly M Tinker, Erin N Madden, et al.
The Annals of Thoracic Surgery|June 30, 2004
Successful surgical management of a neonate with a saddle pulmonary embolusLorraine E De Blanche, Michael L Schmitz, Charles E Johnson, et al.
Diabetes Care|January 29, 2011
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatmentJennie H Best, Richard R Rubin, Mark Peyrot, et al.
Journal of Medical Economics|January 31, 2024
Reduced mortality, complications, and economic burden among medicare beneficiaries receiving influenza antiviralsJennie H Best, Sheila R Reddy, Eunice Chang, et al.
Rheumatology and Therapy|February 25, 2021
Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis RegistryDimitrios A Pappas, Taylor Blachley, Jennie H Best, et al.
Rheumatology and Therapy|May 26, 2021
Comparative Efficacy (DAS28 Remission) of Targeted Immune Modulators for Rheumatoid Arthritis: A Network Meta-AnalysisJennie H Best, Yuting Kuang, Yilin Jiang, et al.
Diabetes & Metabolism|July 26, 2014
Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetesM Bounthavong, J N Tran, S Golshan, et al.
American Journal of Obstetrics and Gynecology|June 6, 2007
Early maturation of sinus rhythm dynamics in high-risk fetusesR B Govindan, Curtis L Lowery, J Quaid Campbell, et al.
Diabetes Care|October 9, 2010
Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink databaseJennie H Best, Byron J Hoogwerf, William H Herman, et al.
Pageof 15

Showing results (121-130 of 142) with videos related to

Sort By:
Pageof 15
Journal of Medical Economics|February 29, 2012
Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United StatesAnne-Laure Guillermin, Adam Lloyd, Jennie H Best, et al.
Food Research International (Ottawa, Ont.)|March 1, 2025
Comparative evaluation of amylases in the oral phase of the INFOGEST static simulation of oro-gastric digestionYunyao Qu, Kelly M Tinker, Erin N Madden, et al.
The Annals of Thoracic Surgery|June 30, 2004
Successful surgical management of a neonate with a saddle pulmonary embolusLorraine E De Blanche, Michael L Schmitz, Charles E Johnson, et al.
Diabetes Care|January 29, 2011
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatmentJennie H Best, Richard R Rubin, Mark Peyrot, et al.
Journal of Medical Economics|January 31, 2024
Reduced mortality, complications, and economic burden among medicare beneficiaries receiving influenza antiviralsJennie H Best, Sheila R Reddy, Eunice Chang, et al.
Rheumatology and Therapy|February 25, 2021
Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis RegistryDimitrios A Pappas, Taylor Blachley, Jennie H Best, et al.
Rheumatology and Therapy|May 26, 2021
Comparative Efficacy (DAS28 Remission) of Targeted Immune Modulators for Rheumatoid Arthritis: A Network Meta-AnalysisJennie H Best, Yuting Kuang, Yilin Jiang, et al.
Diabetes & Metabolism|July 26, 2014
Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetesM Bounthavong, J N Tran, S Golshan, et al.
American Journal of Obstetrics and Gynecology|June 6, 2007
Early maturation of sinus rhythm dynamics in high-risk fetusesR B Govindan, Curtis L Lowery, J Quaid Campbell, et al.
Diabetes Care|October 9, 2010
Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink databaseJennie H Best, Byron J Hoogwerf, William H Herman, et al.
Pageof 15